145 related articles for article (PubMed ID: 26397134)
1. Rapamycin and WYE-354 suppress human gallbladder cancer xenografts in mice.
Weber H; Leal P; Stein S; Kunkel H; García P; Bizama C; Espinoza JA; Riquelme I; Nervi B; Araya JC; Grez M; Roa JC
Oncotarget; 2015 Oct; 6(31):31877-88. PubMed ID: 26397134
[TBL] [Abstract][Full Text] [Related]
2. Preclinical in vivo evaluation of rapamycin in human malignant peripheral nerve sheath explant xenograft.
Bhola P; Banerjee S; Mukherjee J; Balasubramanium A; Arun V; Karim Z; Burrell K; Croul S; Gutmann DH; Guha A
Int J Cancer; 2010 Jan; 126(2):563-71. PubMed ID: 19634141
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic effect of rapamycin on gallbladder cancer in a transgenic mouse model.
Wu Q; Kiguchi K; Kawamoto T; Ajiki T; Traag J; Carbajal S; Ruffino L; Thames H; Wistuba I; Thomas M; Vasquez KM; DiGiovanni J
Cancer Res; 2007 Apr; 67(8):3794-800. PubMed ID: 17440093
[TBL] [Abstract][Full Text] [Related]
4. Histone Deacetylase Inhibitors Inhibit the Proliferation of Gallbladder Carcinoma Cells by Suppressing AKT/mTOR Signaling.
Zhang P; Guo Z; Wu Y; Hu R; Du J; He X; Jiao X; Zhu X
PLoS One; 2015; 10(8):e0136193. PubMed ID: 26287365
[TBL] [Abstract][Full Text] [Related]
5. A potent therapeutics for gallbladder cancer by combinatorial inhibition of the MAPK and mTOR signaling networks.
Mohri D; Ijichi H; Miyabayashi K; Takahashi R; Kudo Y; Sasaki T; Asaoka Y; Tanaka Y; Ikenoue T; Tateishi K; Tada M; Isayama H; Koike K
J Gastroenterol; 2016 Jul; 51(7):711-21. PubMed ID: 26614007
[TBL] [Abstract][Full Text] [Related]
6. Rapamycin and CCI-779 inhibit the mammalian target of rapamycin signalling in hepatocellular carcinoma.
Hui IC; Tung EK; Sze KM; Ching YP; Ng IO
Liver Int; 2010 Jan; 30(1):65-75. PubMed ID: 19845851
[TBL] [Abstract][Full Text] [Related]
7. Curcumin inhibits carcinogen and nicotine-induced Mammalian target of rapamycin pathway activation in head and neck squamous cell carcinoma.
Clark CA; McEachern MD; Shah SH; Rong Y; Rong X; Smelley CL; Caldito GC; Abreo FW; Nathan CO
Cancer Prev Res (Phila); 2010 Dec; 3(12):1586-95. PubMed ID: 20851953
[TBL] [Abstract][Full Text] [Related]
8. Norcantharidin: a potential antiangiogenic agent for gallbladder cancers in vitro and in vivo.
Zhang JT; Fan YZ; Chen CQ; Zhao ZM; Sun W
Int J Oncol; 2012 May; 40(5):1501-14. PubMed ID: 22200632
[TBL] [Abstract][Full Text] [Related]
9. Antineoplastic effect of rapamycin is potentiated by inhibition of IRS-1 signaling in prostate cancer cells xenografts.
Oliveira JC; Souza KK; Dias MM; Faria MC; Ropelle ER; Flores MB; Ueno M; Velloso LA; Saad ST; Saad MJ; Carvalheira JB
J Cancer Res Clin Oncol; 2008 Aug; 134(8):833-9. PubMed ID: 18264722
[TBL] [Abstract][Full Text] [Related]
10. Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2.
Yu K; Shi C; Toral-Barza L; Lucas J; Shor B; Kim JE; Zhang WG; Mahoney R; Gaydos C; Tardio L; Kim SK; Conant R; Curran K; Kaplan J; Verheijen J; Ayral-Kaloustian S; Mansour TS; Abraham RT; Zask A; Gibbons JJ
Cancer Res; 2010 Jan; 70(2):621-31. PubMed ID: 20068177
[TBL] [Abstract][Full Text] [Related]
11. Synergism between the mTOR inhibitor rapamycin and FAK down-regulation in the treatment of acute lymphoblastic leukemia.
Shi PJ; Xu LH; Lin KY; Weng WJ; Fang JP
J Hematol Oncol; 2016 Feb; 9():12. PubMed ID: 26892465
[TBL] [Abstract][Full Text] [Related]
12. Dual inhibition by S6K1 and Elf4E is essential for controlling cellular growth and invasion in bladder cancer.
Kyou Kwon J; Kim SJ; Hoon Kim J; Mee Lee K; Ho Chang I
Urol Oncol; 2014 Jan; 32(1):51.e27-35. PubMed ID: 24239466
[TBL] [Abstract][Full Text] [Related]
13. Norcantharidin inhibits growth of human gallbladder carcinoma xenografted tumors in nude mice by inducing apoptosis and blocking the cell cycle in vivo.
Fan YZ; Zhao ZM; Fu JY; Chen CQ; Sun W
Hepatobiliary Pancreat Dis Int; 2010 Aug; 9(4):414-22. PubMed ID: 20688607
[TBL] [Abstract][Full Text] [Related]
14. Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model.
Lang SA; Gaumann A; Koehl GE; Seidel U; Bataille F; Klein D; Ellis LM; Bolder U; Hofstaedter F; Schlitt HJ; Geissler EK; Stoeltzing O
Int J Cancer; 2007 Apr; 120(8):1803-10. PubMed ID: 17230506
[TBL] [Abstract][Full Text] [Related]
15. Fibronectin promotes cell proliferation and invasion through mTOR signaling pathway activation in gallbladder cancer.
Cao Y; Liu X; Lu W; Chen Y; Wu X; Li M; Wang XA; Zhang F; Jiang L; Zhang Y; Hu Y; Xiang S; Shu Y; Bao R; Li H; Wu W; Weng H; Yen Y; Liu Y
Cancer Lett; 2015 May; 360(2):141-50. PubMed ID: 25657110
[TBL] [Abstract][Full Text] [Related]
16. Rapamycin provides a therapeutic option through inhibition of mTOR signaling in chronic myelogenous leukemia.
Li J; Xue L; Hao H; Han Y; Yang J; Luo J
Oncol Rep; 2012 Feb; 27(2):461-6. PubMed ID: 21993902
[TBL] [Abstract][Full Text] [Related]
17. Temsirolimus inhibits malignant pleural mesothelioma growth in vitro and in vivo: synergism with chemotherapy.
Hoda MA; Mohamed A; Ghanim B; Filipits M; Hegedus B; Tamura M; Berta J; Kubista B; Dome B; Grusch M; Setinek U; Micksche M; Klepetko W; Berger W
J Thorac Oncol; 2011 May; 6(5):852-63. PubMed ID: 21358348
[TBL] [Abstract][Full Text] [Related]
18. Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma.
Huynh H; Chow PK; Palanisamy N; Salto-Tellez M; Goh BC; Lee CK; Somani A; Lee HS; Kalpana R; Yu K; Tan PH; Wu J; Soong R; Lee MH; Hor H; Soo KC; Toh HC; Tan P
J Hepatol; 2008 Jul; 49(1):52-60. PubMed ID: 18490075
[TBL] [Abstract][Full Text] [Related]
19. Downregulation of cancer stem cell properties via mTOR signaling pathway inhibition by rapamycin in nasopharyngeal carcinoma.
Yang C; Zhang Y; Zhang Y; Zhang Z; Peng J; Li Z; Han L; You Q; Chen X; Rao X; Zhu Y; Liao Z
Int J Oncol; 2015 Sep; 47(3):909-17. PubMed ID: 26202311
[TBL] [Abstract][Full Text] [Related]
20. Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition.
Dudkin L; Dilling MB; Cheshire PJ; Harwood FC; Hollingshead M; Arbuck SG; Travis R; Sausville EA; Houghton PJ
Clin Cancer Res; 2001 Jun; 7(6):1758-64. PubMed ID: 11410517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
